Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03868124 · ClinicalTrials.gov registry record · Phase 3
Clinical Study Comparing Two Models of a Travoprost Intraocular Implant
A Phase 3 study, sponsored by Glaukos Corporation.
- Completed
- Registry status
- Phase 3
- Development phase
- 560
- Enrollment target
NCT03868124 is a Phase 3 study that has completed, run by Glaukos Corporation. The registered enrollment target is 560 participants.
The verdict
NCT03868124, a Phase 3 study, has completed, sponsored by Glaukos Corporation.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 560 participants
- Enrollment target
Study Summary
Phase III study to compare the safety and efficacy of intraocular implants containing Travoprost at two different elution rates versus Timolol Maleate Ophthalmic Solution, 0.5% (Timolol) in reducing elevated intraocular pressure in subjects with open angle glaucoma (OAG) or ocular hypertension (OHT)
Interventions
- COMBINATION_PRODUCT G2-TR intraocular implant containing travoprost
- DRUG Sham surgery + active-comparator eye drops
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 560 participants |
| Start Date | 2018-09-17 |
| Est. Completion | 2024-06-19 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03868124
The ClinicalTrials.gov registry entry for NCT03868124 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 560 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Glaukos Corporation, which has 33 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which G2-TR intraocular implant containing travoprost is the first listed.
NCT03868124 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03868124 about?
NCT03868124 is a clinical study titled "Clinical Study Comparing Two Models of a Travoprost Intraocular Implant". Phase III study to compare the safety and efficacy of intraocular implants containing Travoprost at two different elution rates versus Timolol Maleate Ophthalmic Solution, 0.5% (Timolol) in reducing elevated intraocular pressure in subjects with open angle glaucoma (OAG) or ocular hypertension (OHT)
What is the current status of trial NCT03868124?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 560 participants. The study started on 2018-09-17. Estimated completion is 2024-06-19.
What interventions are being tested in trial NCT03868124?
The interventions under investigation include: G2-TR intraocular implant containing travoprost (COMBINATION_PRODUCT), Sham surgery + active-comparator eye drops (DRUG).
Who is sponsoring clinical trial NCT03868124?
This trial is sponsored by Glaukos Corporation, which has 33 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.